<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3386">
  <stage>Registered</stage>
  <submitdate>1/12/2011</submitdate>
  <approvaldate>1/12/2011</approvaldate>
  <nctid>NCT01485601</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines</studytitle>
    <scientifictitle>A Randomised, Double-blind, Multi-centre, Phase II, Optimal Dose-finding Study to Determine the Safety and Efficacy of MT10109 (Clostridium Botulinum Toxin Type A) in Subjects With Moderate to Severe Glabellar Lines in Comparison to BOTOX®</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MT-GPRT-GL01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glabellar Frown Lines</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - MT10109

Experimental: MT10109 - Clostridium botulinum toxin type A

Active Comparator: Botox (registered trade mark) - Clostridium botulinum toxin type A


Other interventions: MT10109
Single dose intramuscular injection MT10109 vs Botox®

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Investigator's rating of glabellar line severity at maximum frown by live assessment.</outcome>
      <timepoint>at Day 30</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults aged between 18 and 75 years with glabellar facial lines of at least moderate
             severity at maximum frown by investigator's assessment.

          -  Women of childbearing potential must have a negative serum pregnancy test at screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with an inability to substantially lessen glabellar lines by physically
             spreading them apart.

          -  Concurrent therapy that, in the investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study medication

          -  Patients with an anaphylactic response history to botulinum toxin type A.

          -  Patients who have been administered botulinum toxin type A within the previous 6
             months.

          -  Pregnant or lactating women.

          -  Participation in any research study involving drug administration within 90 days
             preceding enrollment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>121</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medy-Tox</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find an optimal dose to determine the safety and tolerability
      of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular
      injection in subjects with glabellar lines compared with the standard dose of BOTOX®</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01485601</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Foley, Doctor</name>
      <address>Austrailia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>